Recent trials have demonstrated that sodium-glucose co-transporter 2 inhibitors (SGLT2i) [4] and glucagon-like peptide 1 receptor agonists (GLP1-RA) [5] reduce the incidence of major cardiovascular events in individuals with type 2 diabetes at increased CVD risk, hence opportunities for improved CVD risk prediction in these patients might help to select patients who would derive particular benefit from these treatments. Here, GLP1R is linked to type 2 diabetes mellitus.